{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:14:38Z","timestamp":1793927678671,"version":"4.8.0"},"reference-count":270,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020295","name":"Natera","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020295","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.ajkd.2025.11.006","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:15:27Z","timestamp":1773908127000},"page":"447-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)"],"prefix":"10.1053","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-9961","authenticated-orcid":false,"given":"Neera K.","family":"Dahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"August","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad T.","family":"Chebib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Benjamin D.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Goral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Guay-Woodford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashima","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Lakhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Miskulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Rahbari-Oskoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Watnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib1","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"2S","key":"10.1053\/j.ajkd.2025.11.006_bib2","first-page":"S1","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","year":"2025","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"24","key":"10.1053\/j.ajkd.2025.11.006_bib4","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1001\/jama.2022.22847","article-title":"Exome sequencing of a clinical population for autosomal dominant polycystic kidney disease","volume":"328","author":"Chang","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 mutation carriers develop kidney and liver cysts","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.kint.2022.11.025","article-title":"Individuals heterozygous for ALG8 protein-truncating variants are at increased risk of a mild cystic kidney disease","volume":"103","author":"Apple","year":"2023","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.ekir.2024.04.031","article-title":"A novel monoallelic ALG5 variant causing late-onset ADPKD and tubulointerstitial fibrosis","volume":"9","author":"Elhassan","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ajhg.2021.11.016","article-title":"Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype","volume":"109","author":"Senum","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2025.11.006_bib11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2025.0310","article-title":"Autosomal dominant polycystic kidney disease: a review","volume":"333","author":"Chebib","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1681\/ASN.2014030297","article-title":"Imaging-based diagnosis of autosomal dominant polycystic kidney disease","volume":"26","author":"Pei","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.ajkd.2011.12.022","article-title":"Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors","volume":"59","author":"Rule","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2003.50006","article-title":"Clinical profile of autosomal dominant polycystic liver disease","volume":"37","author":"Qian","year":"2003","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib15","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/316904","article-title":"Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1","volume":"67","author":"Reynolds","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2009.12.005","article-title":"Isolated polycystic liver disease","volume":"17","author":"Qian","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0092-8674(94)90137-6","article-title":"The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16","volume":"77","year":"1994","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2024.05.010","article-title":"Advancing genetic testing in kidney diseases: report from a National Kidney Foundation Working Group","volume":"84","author":"Franceschini","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2025.11.006_bib19","series-title":"GeneReviews","article-title":"Autosomal recessive polycystic kidney disease-PKHD1","author":"Burgmaier","year":"1993"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib20","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.ekir.2023.07.010","article-title":"The phenotypic spectrum of COL4A3 heterozygotes","volume":"8","author":"Solanki","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib21","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI96729","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function","volume":"127","author":"Besse","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","article-title":"Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases","volume":"31","author":"Van Keimpema","year":"2011","journal-title":"Liver Int"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib23","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.kint.2019.08.038","article-title":"Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease","volume":"97","author":"Hopp","year":"2020","journal-title":"Kidney Int"},{"issue":"20","key":"10.1053\/j.ajkd.2025.11.006_bib25","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ki.1983.51","article-title":"Rate of functional deterioration in polycystic kidney disease","volume":"23","author":"Franz","year":"1983","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/ndt\/gfw294","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"15","key":"10.1053\/j.ajkd.2025.11.006_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib32","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.ekir.2023.06.018","article-title":"Clinical characteristics of rapid progression in Asia-Pacific patients with ADPKD","volume":"8","author":"Oh","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1159\/000518255","article-title":"Predicting future renal function decline in patients with autosomal dominant polycystic kidney disease using Mayo Clinic classification","volume":"52","author":"Borrego Utiel","year":"2021","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.23876\/j.krcp.21.261","article-title":"Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study","volume":"41","author":"Park","year":"2022","journal-title":"Kidney Res Clin Pract"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.34067\/KID.0000000000000412","article-title":"Renal hemodynamic and functional changes in patients with ADPKD","volume":"5","author":"Ishii","year":"2024","journal-title":"Kidney360"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.34067\/KID.0000000000000433","article-title":"Clinical characteristics and kidney outcomes in chinese patients with autosomal dominant polycystic kidney disease","volume":"5","author":"Fung","year":"2024","journal-title":"Kidney360"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2215\/CJN.0000000000000427","article-title":"Validation of the Mayo imaging classification system for predicting kidney outcomes in ADPKD","volume":"19","author":"Bais","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"16","key":"10.1053\/j.ajkd.2025.11.006_bib38","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJM199010183231601","article-title":"The diagnosis and prognosis of autosomal dominant polycystic kidney disease","volume":"323","author":"Parfrey","year":"1990","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib39","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"Muller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib41","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.ekir.2020.06.011","article-title":"Estimation of changes in kidney volume growth rate in ADPKD","volume":"5","author":"Higashihara","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100538","article-title":"The STAGED-PKD 2-Stage Adaptive Study with a patient enrichment strategy and treatment effect modeling for improved study design efficiency in patients with ADPKD","volume":"4","author":"Perrone","year":"2022","journal-title":"Kidney Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib43","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","article-title":"Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)","volume":"46","author":"O\u2019Neill","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2215\/CJN.14931121","article-title":"Total kidney volume measurements in ADPKD by 3D and ellipsoid ultrasound in comparison with magnetic resonance imaging","volume":"17","author":"Akbari","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib46","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib47","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"issue":"3S","key":"10.1053\/j.ajkd.2025.11.006_bib48","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.ajkd.2021.09.013","article-title":"KDOQI US commentary on the 2021 KDIGO clinical practice guideline for the management of blood pressure in CKD","volume":"79","author":"Drawz","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib50","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"24","key":"10.1053\/j.ajkd.2025.11.006_bib51","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2024.06.020","article-title":"Effect of dual RAAS blockade and intensive BP lowering on risk of end-stage kidney disease and death in autosomal dominant polycystic kidney disease: long-term follow-up of the HALT-PKD trials","volume":"85","author":"Ku","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"10.1053\/j.ajkd.2025.11.006_bib53","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib54","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ndt\/gfaa150","article-title":"Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study","volume":"36","author":"Kramers","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.ki.5002629","article-title":"Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy\/+ rat","volume":"73","author":"Nagao","year":"2008","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(00)70195-8","article-title":"Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease","volume":"35","author":"Ecder","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib57","doi-asserted-by":"crossref","first-page":"c18","DOI":"10.1159\/000081790","article-title":"Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease","volume":"99","author":"Nutahara","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/oxfordjournals.qjmed.a030139","article-title":"Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease","volume":"89","author":"Kanno","year":"1996","journal-title":"QJM"},{"issue":"24","key":"10.1053\/j.ajkd.2025.11.006_bib59","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib61","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000046231","article-title":"Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease","volume":"21","author":"Ecder","year":"2001","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1470320312452767","article-title":"Delayed diagnosis of primary aldosteronism in patients with autosomal dominant polycystic kidney diseases","volume":"14","author":"Kao","year":"2013","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ndt\/7.7.647","article-title":"Autosomal dominant polycystic kidney disease with primary hyperaldosteronism","volume":"7","author":"Bobrie","year":"1992","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib64","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/archinte.1978.03630330080024","article-title":"Renal artery stenosis and polycystic kidney disease","volume":"138","author":"Messerli","year":"1978","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib65","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3109\/0886022X.2014.918831","article-title":"Renal artery occlusion in autosomal dominant polycystic kidney disease","volume":"36","author":"Sanchez","year":"2014","journal-title":"Ren Fail"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00129689-200402000-00010","article-title":"Bilateral endoscopic adrenalectomy for Cushing\u2019s syndrome in a patient with polycystic liver and kidney disease","volume":"14","author":"Niemann","year":"2004","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mcna.2021.11.004","article-title":"Evaluation and management of secondary hypertension","volume":"106","author":"Sarathy","year":"2022","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.ajkd.2025.11.006_bib68","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1100\/tsw.2011.94","article-title":"Nephrotic syndrome and idiopathic membranous nephropathy associated with autosomal-dominant polycystic kidney disease","volume":"11","author":"Peces","year":"2011","journal-title":"ScientificWorldJournal"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib69","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/ckj\/sfs147","article-title":"Nephrotic syndrome and autosomal dominant polycystic kidney disease","volume":"5","author":"Visciano","year":"2012","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib70","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10157-005-0403-6","article-title":"Nephrotic syndrome and IgA nephropathy in polycystic kidney disease","volume":"10","author":"Hiura","year":"2006","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/1596-3519.179735","article-title":"Co-existing autosomal dominant polycystic kidney disease and nephrotic syndrome in a Nigerian patient with lupus nephritis","volume":"15","author":"Akinbodewa","year":"2016","journal-title":"Ann Afr Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12882-019-1524-6","article-title":"PKD1-associated autosomal dominant polycystic kidney disease with glomerular cysts presenting with nephrotic syndrome caused by focal segmental glomerulosclerosis","volume":"20","author":"Oda","year":"2019","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib73","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1681\/ASN.V651354","article-title":"Nephrotic syndrome in autosomal dominant polycystic kidney disease","volume":"6","author":"Contreras","year":"1995","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib74","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.bja.2019.03.023","article-title":"Chronic pain: a review of its epidemiology and associated factors in population-based studies","volume":"123","author":"Mills","year":"2019","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2214\/ajr.159.1.1609726","article-title":"Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients","volume":"159","author":"Levine","year":"1992","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.ajkd.2025.11.006_bib76","series-title":"Understanding radiation risk from imaging tests","year":"2018"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib77","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s10157-023-02378-2","article-title":"Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study","volume":"27","author":"Chasan","year":"2023","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib78","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2215\/CJN.13861119","article-title":"Urinary lithogenic risk profile in ADPKD patients treated with tolvaptan","volume":"15","author":"Bargagli","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.11.006_bib79","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3483172","article-title":"Percutaneous nephrolithotomy under ultrasound guidance in patients with renal calculi and autosomal dominant polycystic kidney disease: a report of 11 cases","volume":"2017","author":"Wang","year":"2017","journal-title":"Adv Urol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/end.2013.0443","article-title":"Safety and efficacy of minimally invasive percutaneous nephrolithotomy in patients with autosomal dominant polycystic kidney disease","volume":"28","author":"Lei","year":"2014","journal-title":"J Endourol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5489\/cuaj.7872","article-title":"Update: Canadian Urological Association guideline: evaluation and medical management of kidney stones","volume":"16","author":"Bhojani","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0272-6386(12)80922-X","article-title":"Renal stone disease in autosomal dominant polycystic kidney disease","volume":"22","author":"Torres","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib83","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.ajkd.2025.11.006_bib84","article-title":"FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)","year":"2019","journal-title":"FDA Drug Safety Communication"},{"issue":"13","key":"10.1053\/j.ajkd.2025.11.006_bib85","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib86","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JU.0000000000000296","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"Anger","year":"2019","journal-title":"J Urol"},{"key":"10.1053\/j.ajkd.2025.11.006_bib87","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study","volume":"360","author":"Pasternak","year":"2018","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2025.11.006_bib88","article-title":"FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients","volume":"20","year":"2018","journal-title":"FDA Drug Safety Communication, December"},{"issue":"42","key":"10.1053\/j.ajkd.2025.11.006_bib89","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1093\/eurheartj\/ehad660","article-title":"Concerns about aortic aneurysm or dissection risk should not cease fluoroquinolone use when clinically indicated","volume":"44","author":"Tamargo","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib90","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamasurg.2020.6165","article-title":"Association of fluoroquinolone use with short-term risk of development of aortic aneurysm","volume":"156","author":"Newton","year":"2021","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib91","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/STROKEAHA.119.028490","article-title":"Risk of intracranial aneurysm and dissection and fluoroquinolone use: a case-time-control study","volume":"51","author":"Maumus-Robert","year":"2020","journal-title":"Stroke"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib92","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1681\/ASN.V491661","article-title":"Renal cell carcinoma in autosomal dominant polycystic kidney disease","volume":"4","author":"Keith","year":"1994","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib93","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/cancers11030422","article-title":"Renal cell carcinoma with sarcomatoid features: finally new therapeutic hope?","volume":"11","author":"Pichler","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.ajkd.2025.11.006_bib94","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib95","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.34067\/KID.0007422020","article-title":"Examining the role of novel CKD therapies for the ADPKD patient","volume":"2","author":"Patel","year":"2021","journal-title":"Kidney360"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib96","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib97","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1053\/j.ajkd.2025.11.006_bib99","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/ndt\/gfaf061","article-title":"SGLT2 inhibition for patients with ADPKD\u2014closing the evidence gap","volume":"40","author":"M\u00fcller","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib100","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The potential for renoprotection with incretin-based drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.11.006_bib101","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"2S1","key":"10.1053\/j.ajkd.2025.11.006_bib102","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ajt.2024.01.012","article-title":"OPTN\/SRTR 2022 annual data report: kidney","volume":"24","author":"Lentine","year":"2024","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15216","article-title":"The effect of primary renal disease upon outcomes after renal transplant","volume":"38","author":"Garland","year":"2024","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib107","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1432-2277.2011.01237.x","article-title":"Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study","volume":"24","author":"Jacquet","year":"2011","journal-title":"Transplant Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib114","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.transproceed.2009.01.069","article-title":"Autosomal-dominant polycystic kidney disease and kidney transplantation: experience of a single center","volume":"41","author":"Goncalves","year":"2009","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib104","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcjd.2016.03.001","article-title":"The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis","volume":"40","author":"Cheungpasitporn","year":"2016","journal-title":"Can J Diabetes"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12882-021-02231-2","article-title":"Contemporary incidence and risk factors of post transplant erythrocytosis in deceased donor kidney transplantation","volume":"22","author":"Alasfar","year":"2021","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib106","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5500\/wjt.v11.i6.220","article-title":"Post-transplant erythrocytosis after kidney transplantation: a review","volume":"11","author":"Alzoubi","year":"2021","journal-title":"World J Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib108","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/tri.14016","article-title":"Risk factors and outcomes of post-transplant erythrocytosis among adult kidney transplant recipients: a systematic review and meta-analysis","volume":"34","author":"Mekraksakit","year":"2021","journal-title":"Transpl Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib109","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ekir.2022.01.1062","article-title":"Incidence, risk factors and outcomes of kidney and liver cyst infection in kidney transplant recipient with ADPKD","volume":"7","author":"Ronsin","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib110","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.ekir.2022.06.006","article-title":"Cardiovascular outcomes in kidney transplant recipients with ADPKD","volume":"7","author":"Chedid","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib111","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/jcm8040524","article-title":"Subarachnoid hemorrhage in hospitalized renal transplant recipients with autosomal dominant polycystic kidney disease: a nationwide analysis","volume":"8","author":"Cheungpasitporn","year":"2019","journal-title":"J Clin Med"},{"key":"10.1053\/j.ajkd.2025.11.006_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1017498","article-title":"Skin cancer outcomes and risk factors in renal transplant recipients: analysis of organ procurement and transplantation network data from 2000 to 2021","volume":"12","author":"Hao","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00384-020-03736-2","article-title":"Colonic diverticular disease in autosomal dominant polycystic kidney disease: is there really an association? A nationwide analysis","volume":"36","author":"Duarte-Chavez","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2215\/CJN.00840122","article-title":"Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States","volume":"17","author":"McGill","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100577","article-title":"Health disparities in kidney failure among patients with autosomal dominant polycystic kidney disease: a cross-sectional study","volume":"5","author":"Harrison","year":"2023","journal-title":"Kidney Med"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib117","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15315","article-title":"Expanding the access to kidney transplantation: strategies for kidney transplant programs","volume":"38","author":"Nishio Lucar","year":"2024","journal-title":"Clin Transplant"},{"issue":"4 suppl 1","key":"10.1053\/j.ajkd.2025.11.006_bib118","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib119","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/TXD.0000000000000554","article-title":"Native nephrectomy in renal transplant recipients with autosomal dominant polycystic kidney disease","volume":"1","author":"Chebib","year":"2015","journal-title":"Transplant Direct"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/TP.0000000000000838","article-title":"Live donor renal transplant with simultaneous bilateral nephrectomy for autosomal dominant polycystic kidney disease is feasible and satisfactory at long-term follow-up","volume":"100","author":"Ahmad","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib121","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/ajt.16310","article-title":"Simultaneous bilateral laparoscopic nephrectomy with kidney transplantation in patients with ESRD due to ADPKD: a single-center experience","volume":"21","author":"Abrol","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib122","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000525575","article-title":"The need for routine native nephrectomy in the workup for kidney transplantation in autosomal dominant polycystic kidney disease patients","volume":"107","author":"Casteleijn","year":"2023","journal-title":"Urol Int"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib123","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5500\/wjt.v12.i5.100","article-title":"Simultaneous nephrectomy during kidney transplantation for polycystic kidney disease does not detrimentally impact comorbidity and graft survival","volume":"12","author":"Darius","year":"2022","journal-title":"World J Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib124","doi-asserted-by":"crossref","DOI":"10.4293\/JSLS.2020.00107","article-title":"Laparoscopic nephrectomy for massive kidneys in polycystic kidney disease","volume":"25","author":"Collini","year":"2021","journal-title":"JSLS"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000536245","article-title":"Prevalence of renal neoplasia in autosomal dominant polycystic kidney disease: systematic review and meta-analysis","volume":"148","author":"Drake","year":"2024","journal-title":"Nephron"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib126","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group ii gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"25","key":"10.1053\/j.ajkd.2025.11.006_bib127","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2025.11.006_bib128","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib129","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100639","article-title":"Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies","volume":"5","author":"Chebib","year":"2023","journal-title":"Kidney Med"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib131","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","article-title":"Evaluating the impact of a risk evaluation and mitigation strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Estilo","year":"2022","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib132","article-title":"Pos-337 Canadian real-world assessment of tolvaptan in ADPKD: C-Major study and safety monitoring and distribution program","volume":"6","author":"McFarlane","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib133","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12882-021-02607-4","article-title":"Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN dataset","volume":"22","author":"Thomas","year":"2021","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib134","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib135","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","article-title":"Tolvaptan in ADPKD patients with very low kidney function","volume":"6","author":"Torres","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib136","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib137","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib138","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100021","article-title":"Prescribed water intake in autosomal dominant polycystic kidney disease","volume":"1","author":"Rangan","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib139","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","article-title":"Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial","volume":"68","author":"Amro","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib140","doi-asserted-by":"crossref","first-page":"698","DOI":"10.34067\/KID.0000000000000428","article-title":"Feasibility of water therapy for slowing autosomal dominant polycystic kidney disease progression","volume":"5","author":"Dev","year":"2024","journal-title":"Kidney360"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib141","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib142","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09900915","article-title":"Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3B-4","volume":"11","author":"Ruggenenti","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib143","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib144","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib145","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib146","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.kint.2025.08.037","article-title":"A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease","volume":"109","author":"Gitomer","year":"2026","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib148","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"issue":"9903","key":"10.1053\/j.ajkd.2025.11.006_bib149","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib150","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2215\/CJN.13661119","article-title":"Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: a randomized clinical trial","volume":"15","author":"Hogan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2025.11.006_bib151","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"issue":"15","key":"10.1053\/j.ajkd.2025.11.006_bib153","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diabet.2019.11.006","article-title":"SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes","volume":"46","author":"Lytvyn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"19","key":"10.1053\/j.ajkd.2025.11.006_bib156","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.3390\/jcm12196341","article-title":"Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease-a retrospective single-arm case series study","volume":"12","author":"Morioka","year":"2023","journal-title":"J Clin Med"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib158","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.0000000725","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy and longitudinal changes in kidney function among veterans with autosomal dominant polycystic kidney disease","volume":"20","author":"Eswarappa","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib159","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib160","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib161","article-title":"Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial","volume":"4","author":"Cukoski","year":"2023","journal-title":"Cell Rep Med"},{"issue":"18","key":"10.1053\/j.ajkd.2025.11.006_bib162","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jama.280.18.1569","article-title":"Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey","volume":"280","author":"Eisenberg","year":"1998","journal-title":"JAMA"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib163","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/liv.14986","article-title":"Estrogens in polycystic liver disease: a target for future therapies?","volume":"41","author":"Aapkes","year":"2021","journal-title":"Liver Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib164","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/ndt\/gfw008","article-title":"Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease","volume":"31","author":"Chebib","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib165","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/cpt.1553","article-title":"Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients","volume":"106","author":"Van Aerts","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib166","first-page":"1282","article-title":"Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease","volume":"26","author":"Sherstha","year":"1997","journal-title":"Hepatology"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib167","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"issue":"19","key":"10.1053\/j.ajkd.2025.11.006_bib168","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMp1402080","article-title":"FDA approval of paroxetine for menopausal hot flushes","volume":"370","author":"Orleans","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib169","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG Practice Bulletin No. 141: management of menopausal symptoms","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"32","key":"10.1053\/j.ajkd.2025.11.006_bib170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026797","article-title":"Tamoxifen for the treatment of polycystic liver disease: a case report","volume":"100","author":"Aapkes","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib171","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12876-022-02142-y","article-title":"Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study","volume":"22","author":"Aapkes","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"13","key":"10.1053\/j.ajkd.2025.11.006_bib172","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.cgh.2015.05.039","article-title":"Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease","volume":"13","author":"Temmerman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib173","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/15269248221132255","article-title":"Effect of preoperative sarcopenia, malnutrition and functional status on postoperative morbidity following liver transplantation","volume":"32","author":"Prakash","year":"2022","journal-title":"Prog Transplant"},{"key":"10.1053\/j.ajkd.2025.11.006_bib174","author":"Camurus"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib175","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/ijms21051682","article-title":"Somatostatin analogs in clinical practice: a review","volume":"21","author":"Gomes-Porras","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib176","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib177","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","article-title":"Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease","volume":"90","author":"Hogan","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib178","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib179","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hep.28545","article-title":"Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease","volume":"64","author":"Neijenhuis","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2025.11.006_bib181","article-title":"QT Drugs: Drugs causing QT prolongation, torsade de pointes (TdP) and long QT syndrome (LQTS)","year":"2025","journal-title":"Cardiovascular Medicine"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib182","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.21563","article-title":"The model for end-stage liver disease (MELD)","volume":"45","author":"Kamath","year":"2007","journal-title":"Hepatology"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib183","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/LVT.0000000000000414","article-title":"Policy corner: polycystic liver disease MELD exception update","volume":"30","author":"Mehta","year":"2024","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib184","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jpen.1440","article-title":"GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community","volume":"43","author":"Jensen","year":"2019","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0148607110389335","article-title":"A.S.P.E.N. clinical guidelines: nutrition screening, assessment, and intervention in adults","volume":"35","author":"Mueller","year":"2011","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib186","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ncp.10613","article-title":"Evaluation of nutrition status using the subjective global assessment: malnutrition, cachexia, and sarcopenia","volume":"36","author":"Duerksen","year":"2021","journal-title":"Nutr Clin Pract"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib187","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ndt\/gfu227","article-title":"Diagnostic criteria in renal and hepatic cyst infection","volume":"30","author":"Lantinga","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib188","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2967\/jnumed.117.199448","article-title":"(18)F-FDG PET\/CT in autosomal dominant polycystic kidney disease patients with suspected cyst infection","volume":"59","author":"Pijl","year":"2018","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib189","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease","volume":"11","author":"Perrone","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib190","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(11)70109-0","article-title":"Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis","volume":"10","author":"Vlak","year":"2011","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib191","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2215\/CJN.14691218","article-title":"Presymptomatic screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease","volume":"14","author":"Sanchis","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib192","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/ndt\/gfac027","article-title":"Diagnosis and risk factors for intracranial aneurysms in autosomal polycystic kidney disease: a cross-sectional study from the Genkyst cohort","volume":"37","author":"Lefevre","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib193","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1161\/STR.0000000000000070","article-title":"Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Thompson","year":"2015","journal-title":"Stroke"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib194","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.akdh.2023.09.004","article-title":"Vascular complications in autosomal dominant polycystic kidney disease: perspectives, paradigms, and current state of play","volume":"30","author":"Gulati","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib195","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/j.ajkd.2015.04.044","article-title":"Therapeutic area data standards for autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","volume":"66","author":"Perrone","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib196","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00062-021-01050-0","article-title":"MR Brain screening in ADPKD patients: to screen or not to screen?","volume":"32","author":"Capelli","year":"2022","journal-title":"Clin Neuroradiol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib197","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/01.ASN.0000118527.74850.66","article-title":"Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: a prospective ten-year follow-up","volume":"15","author":"Schrier","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib198","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1161\/STROKEAHA.115.008221","article-title":"Minimally invasive microsurgery for cerebral aneurysms","volume":"46","author":"Wong","year":"2015","journal-title":"Stroke"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib199","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/svn-2019-000303","article-title":"Advances in endovascular aneurysm management: coiling and adjunctive devices","volume":"5","author":"Campos","year":"2020","journal-title":"Stroke Vasc Neurol"},{"issue":"15","key":"10.1053\/j.ajkd.2025.11.006_bib200","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018373","article-title":"Association between hospital volumes and clinical outcomes for patients with nontraumatic subarachnoid hemorrhage","volume":"10","author":"Leifer","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib201","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.V95837","article-title":"Coronary aneurysms in patients with autosomal dominant polycystic kidney disease","volume":"9","author":"Hadimeri","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"934","key":"10.1053\/j.ajkd.2025.11.006_bib202","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/pmj.79.934.474","article-title":"Bilateral popliteal aneurysms complicating adult polycystic kidney disease in a patient with a marfanoid habitus","volume":"79","author":"Al-Hakim","year":"2003","journal-title":"Postgrad Med J"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib203","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228552","article-title":"Splenic artery aneurysm in a patient of autosomal dominant polycystic kidney disease: beyond tenuous concomitance","volume":"12","author":"Sood","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"34","key":"10.1053\/j.ajkd.2025.11.006_bib204","doi-asserted-by":"crossref","first-page":"57594","DOI":"10.18632\/oncotarget.16338","article-title":"Risk of aortic aneurysm and dissection in patients with autosomal-dominant polycystic kidney disease: a nationwide population-based cohort study","volume":"8","author":"Sung","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib205","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.V461371","article-title":"A kindred exhibiting cosegregation of an overlap connective tissue disorder and the chromosome 16 linked form of autosomal dominant polycystic kidney disease","volume":"4","author":"Somlo","year":"1993","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2025.11.006_bib206","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.119.043756","article-title":"Inherited thoracic aortic disease: new insights and translational targets","volume":"141","author":"Fletcher","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2025.11.006_bib207","series-title":"Dietary Guidelines for Americans, 2020-2025","year":"2020"},{"issue":"935","key":"10.1053\/j.ajkd.2025.11.006_bib208","first-page":"1","article-title":"Protein and amino acid requirements in human nutrition","year":"2007","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib209","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2215\/CJN.0000000000000326","article-title":"Polycystic kidney disease diet: what is known and what is safe","volume":"19","author":"Chebib","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib210","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/j.ajkd.2024.02.014","article-title":"Visceral adiposity and progression of ADPKD: a cohort study of patients from the TEMPO 3:4 trial","volume":"84","author":"Nowak","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib211","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ekir.2019.01.003","article-title":"The effect of enlarged kidneys on calculated body mass index categorization in transplant recipients with ADPKD","volume":"4","author":"Freise","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"190","key":"10.1053\/j.ajkd.2025.11.006_bib212","first-page":"1","article-title":"National Health and Nutrition Examination Survey, 2017-March 2020 Prepandemic File: Sample Design, Estimation, and Analytic Guidelines","volume":"1","author":"Akinbami","year":"2022","journal-title":"Vital Health Stat"},{"key":"10.1053\/j.ajkd.2025.11.006_bib213","series-title":"Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960-1962 through 2017-2018","author":"Fryar","year":"2021"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib214","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease","volume":"63","author":"Schrier","year":"2003","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2012.12.018","article-title":"Changing referral characteristics of patients with autosomal dominant polycystic kidney disease","volume":"126","author":"Helal","year":"2013","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib216","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib217","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.ajkd.2024.02.016","article-title":"Kidney energetics and cyst burden in autosomal dominant polycystic kidney disease: a pilot study","volume":"84","author":"Bjornstad","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib218","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/ndt\/gfr744","article-title":"The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease","volume":"27","author":"Reed","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"42","key":"10.1053\/j.ajkd.2025.11.006_bib220","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.15585\/mmwr.mm7042a4","article-title":"Temporal trends in dietary sodium intake among adults aged >\/=19 years\u2014United States, 2003-2016","volume":"70","author":"Clarke","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib221","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib222","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1249\/MSS.0b013e3181949333","article-title":"Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults","volume":"41","author":"Donnelly","year":"2009","journal-title":"Med Sci Sports Exerc"},{"issue":"14","key":"10.1053\/j.ajkd.2025.11.006_bib223","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/archinte.168.14.1550","article-title":"Effect of exercise on 24-month weight loss maintenance in overweight women","volume":"168","author":"Jakicic","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib224","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ntr\/ntaa071","article-title":"Smoking, smoking cessation, and progression of chronic kidney disease: results from KNOW-CKD study","volume":"23","author":"Lee","year":"2021","journal-title":"Nicotine Tob Res"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib225","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population","volume":"291","author":"Fox","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib226","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1080\/0886022X.2021.1949348","article-title":"The effect of smoking on endothelial dysfunction in autosomal dominant polycystic kidney disease patients with preserved renal function","volume":"43","author":"Gul","year":"2021","journal-title":"Ren Fail"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib227","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40620-017-0396-8","article-title":"Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study","volume":"31","author":"Girardat-Rotar","year":"2018","journal-title":"J Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib228","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.33594\/000000072","article-title":"Caffeine accelerates cystic kidney disease in a Pkd1-deficient mouse model","volume":"52","author":"Meca","year":"2019","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib229","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12882-018-1182-0","article-title":"Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort","volume":"19","author":"McKenzie","year":"2018","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib230","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ndt\/gfv010","article-title":"A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research","volume":"30","author":"Tong","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2025.11.006_bib231","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ndt\/gfv299","article-title":"Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease","volume":"31","author":"Simms","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib232","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/j.ajkd.2009.03.016","article-title":"Validation of depression screening scales in patients with CKD","volume":"54","author":"Hedayati","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib233","doi-asserted-by":"crossref","first-page":"159","DOI":"10.34067\/KID.0000000652","article-title":"Mission and future plans for the Autosomal Dominant Polycystic Kidney Disease Centers of Excellence program","volume":"6","author":"Hoover","year":"2025","journal-title":"Kidney360"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib234","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2020.12.022","article-title":"Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients","volume":"74","author":"Rahim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2025.11.006_bib235","series-title":"Menopause: diagnosis and management","year":"2019"},{"issue":"24","key":"10.1053\/j.ajkd.2025.11.006_bib236","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2021.21392","article-title":"Contraception selection, effectiveness, and adverse effects: a review","volume":"326","author":"Teal","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib237","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2018.01.048","article-title":"Preimplantation genetic diagnosis counseling in autosomal dominant polycystic kidney disease","volume":"72","author":"Murphy","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib238","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1681\/ASN.0000000000000253","article-title":"State of the science and ethical considerations for preimplantation genetic testing for monogenic cystic kidney diseases and ciliopathies","volume":"35","author":"Thompson","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib239","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.akdh.2023.10.006","article-title":"Pregnancy in autosomal dominant polycystic kidney disease","volume":"30","author":"Al Sayyab","year":"2023","journal-title":"Adv Kidney Dis Health"},{"key":"10.1053\/j.ajkd.2025.11.006_bib240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib241","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/humu.22103","article-title":"Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients","volume":"33","author":"Audr\u00e9zet","year":"2012","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib242","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/molehr\/gah128","article-title":"PGD for autosomal dominant polycystic kidney disease type 1","volume":"11","author":"De Rycke","year":"2005","journal-title":"Mol Hum Reprod"},{"key":"10.1053\/j.ajkd.2025.11.006_bib243","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12882-015-0015-7","article-title":"A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease","volume":"16","author":"Ali","year":"2015","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib245","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41436-020-01026-4","article-title":"Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease","volume":"23","author":"Durkie","year":"2021","journal-title":"Genet Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2023.104753","article-title":"Novel multi-allelic variants, two BBS2 and one PKD1 variant, of renal ciliopathies: a case report and literature review","volume":"66","author":"Zhong","year":"2023","journal-title":"Eur J Med Genet"},{"issue":"5","key":"10.1053\/j.ajkd.2025.11.006_bib246","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/humrep\/dez027","article-title":"Factors influencing the clinical outcome of preimplantation genetic testing for polycystic kidney disease","volume":"34","author":"Berckmoes","year":"2019","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib247","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/AOG.0000000000004928","article-title":"Roe v Wade and the threat to fertility care","volume":"140","author":"Feinberg","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib248","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/ndt\/gfaa247","article-title":"The impact of chronic kidney disease stages 3-5 on pregnancy outcomes","volume":"36","author":"Wiles","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib249","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.kint.2022.10.029","article-title":"Glomerular diseases in pregnancy: pragmatic recommendations for clinical management","volume":"103","author":"Fakhouri","year":"2023","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib250","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1681\/ASN.2014050459","article-title":"Risk of adverse pregnancy outcomes in women with CKD","volume":"26","author":"Piccoli","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2025.11.006_bib251","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2201295","article-title":"Treatment for mild chronic hypertension during pregnancy","volume":"386","author":"Tita","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib252","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1258\/om.2009.090019","article-title":"Serum cystatin is not a marker of glomerular filtration rate in pregnancy","volume":"2","author":"Bramham","year":"2009","journal-title":"Obstet Med"},{"key":"10.1053\/j.ajkd.2025.11.006_bib253","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.preghy.2019.03.006","article-title":"Serum cystatin-C as predictive factor of preeclampsia: a meta-analysis of 27 observational studies","volume":"16","author":"Bellos","year":"2019","journal-title":"Pregnancy Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib254","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ekir.2018.10.015","article-title":"Serum creatinine in pregnancy: a systematic review","volume":"4","author":"Wiles","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12882-019-1560-2","article-title":"Clinical practice guideline on pregnancy and renal disease","volume":"20","author":"Wiles","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2025.11.006_bib256","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","article-title":"The 2021 International Society for the Study of Hypertension in pregnancy classification, diagnosis & management recommendations for international practice","volume":"27","author":"Magee","year":"2022","journal-title":"Pregnancy Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib257","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1161\/HYPERTENSIONAHA.124.23411","article-title":"Predictive and diagnostic value of the angiogenic proteins in patients with chronic kidney disease","volume":"81","author":"Melamed","year":"2024","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ajkd.2025.11.006_bib258","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/AOG.0000000000005269","article-title":"Urinary tract infections in pregnant individuals","volume":"142","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib259","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/phar.1649","article-title":"A review of antibiotic use in pregnancy","volume":"35","author":"Bookstaver","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib260","doi-asserted-by":"crossref","first-page":"F1315","DOI":"10.1152\/ajprenal.00071.2020","article-title":"Preeclampsia beyond pregnancy: long-term consequences for mother and child","volume":"318","author":"Turbeville","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib261","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ajog.2020.03.016","article-title":"Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis","volume":"223","author":"Bellos","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.11.006_bib262","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2215\/CJN.15121219","article-title":"Updates in diagnosis and management of preeclampsia in women with CKD","volume":"15","author":"Wiles","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.11.006_bib263","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib264","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000448695","article-title":"Long-term outcomes in patients with very-early onset autosomal dominant polycystic kidney disease","volume":"44","author":"Nowak","year":"2016","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1067\/mob.2001.109398","article-title":"The relationship between oligohydramnios and the onset of preterm labor in preterm premature rupture of membranes","volume":"184","author":"Park","year":"2001","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib266","doi-asserted-by":"crossref","first-page":"387","DOI":"10.34067\/KID.0000000000000064","article-title":"Hypomorphic PKD1 alleles impact disease variability in autosomal dominant polycystic kidney disease","volume":"4","author":"Gulati","year":"2023","journal-title":"Kidney360"},{"issue":"1","key":"10.1053\/j.ajkd.2025.11.006_bib267","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71956-1","article-title":"Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD)","volume":"10","author":"Burgmaier","year":"2020","journal-title":"Sci Rep"},{"issue":"17","key":"10.1053\/j.ajkd.2025.11.006_bib268","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","article-title":"Strict blood-pressure control and progression of renal failure in children","volume":"361","author":"Wuhl","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.11.006_bib269","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1097\/HJH.0000000000001039","article-title":"2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents","volume":"34","author":"Lurbe","year":"2016","journal-title":"J Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2025.11.006_bib270","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41581-019-0155-2","article-title":"International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people","volume":"15","author":"Gimpel","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib271","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"10.1053\/j.ajkd.2025.11.006_bib272","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1904","article-title":"Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"issue":"4","key":"10.1053\/j.ajkd.2025.11.006_bib273","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bmjebm-2022-112068","article-title":"Shared decision-making as a method of care","volume":"28","author":"Montori","year":"2023","journal-title":"BMJ Evid Based Med"},{"issue":"8","key":"10.1053\/j.ajkd.2025.11.006_bib274","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.34067\/KID.0002372022","article-title":"Design and basic characteristics of a national patient-powered registry in ADPKD","volume":"3","author":"Hoover","year":"2022","journal-title":"Kidney360"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862600003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862600003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:47:26Z","timestamp":1776102446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263862600003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":270,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S027263862600003X"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.11.006","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}